Form 4 · Filed Jul 20, 2026, 09:30 PM UTC
CBIO/CRESCENT BIOPHARMA, INC.
Fairmount Funds Management LLC — director
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
2 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 16, 2026 | P | buy | 853,450 | $15 | $12,375,025 | 3,601,316 |
| Jul 16, 2026 | P | buy | 525,897 | — | — | 2,294,037 |
Source: SEC EDGAR raw filing ↗ · Accession 0001104659-26-085113